MARKET

GNMX

Aevi Genomic Med
GNMX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.3309
-
-3.1067
12,892,716.43
Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6%
Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights to develop, manufacture and commercialize CERC-002 monoclonal antibody
Seekingalpha · 03/29 11:14
CERC: Improved Balance Sheet to Move the Pipeline Forward
Zacks Small Cap Research · 05/13/2020 11:00
CERC: Data from CDG-FIRST Trial Upcoming
Zacks Small Cap Research · 03/19/2020 13:50
Done deal: Maryland biopharm firm completes acquisition of Aevi Genomic Medicine
American City Business Journals · 02/04/2020 18:31
Cerecor and Aevi Genomic Medicine Complete Merger
GlobeNewswire · 02/03/2020 21:15
Aevi Genomic Medicine, Inc. (GNMX): Hedge Fund Sentiment Unchanged
Insider Monkey · 12/22/2019 22:08
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
GlobeNewswire · 12/16/2019 12:30
CERC: Expansion in Rare and Orphan Diseases with Acquisition of Aevi Genomic Medicine…
Zacks Small Cap Research · 12/13/2019 14:50
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNMX. Analyze the recent business situations of Aevi Genomic Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNMX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 4.96M
% Owned: 6.38%
Shares Outstanding: 77.71M
TypeInstitutionsShares
Increased
3
1.43M
New
6
137.62K
Decreased
7
587.98K
Sold Out
3
378.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.33%
Pharmaceuticals & Medical Research
+0.46%
Key Executives
Non-Executive Chairman
Sol Barer
President/Chief Executive Officer/Director
Michael Cola
Chief Financial Officer
Michael McInaw
Chief Scientific Officer
Garry Neil
Director
Matthew Bayley
Independent Director
Eugene Bauer
Independent Director
Alastair Clemow
Independent Director
Barbara Duncan
Independent Director
Joseph Grano
No Data

Webull offers kinds of Aevi Genomic Med stock information, including NASDAQ:GNMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNMX stock methods without spending real money on the virtual paper trading platform.